Category: Cardiac Rhythm Management
CorMatrix secure FDA clearance for its CanGaroo ECM envelope for use with implantable cardiac devices and touts 1st human use in a patient at Ohio's Cleveland Clinic.
Georgia medical device maker CorMatrix touted an FDA win this month, landing regulatory clearance for its CanGaroo surgical envelope for securing implantable cardiac devices.
Roswell, Georgia – CorMatrix Cardiovascular announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix CanGaroo ECM Envelope for use with cardiac implantable electronic devices (CIED's) including pacemakers and implantable cardioverter defibrillators (ICD's).
Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.
Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.
A federal judge agrees to toss a lawsuit filed against Johnson & Johnson's Biosense Webster by a former sales rep and her new employer, St. Jude Medical.
FDA regulators approve Medtronic's new Viva CRT-P adaptive cardiac pacemaker for treatment of heart failure or atrioventricular block.
Medtronic (NYSE:MDT) won FDA approval for its Viva CRT-P cardiac resynchronization therapy-pacemaker, which features proprietary software to adjust its pacing parameters to a patient's heart rhythms minute-by-minute.
AdaptivCRT algorithm customizes therapy for heart failure patients and improves their response rates.
MINNEAPOLIS - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.
FDA regulators grant AliveCor new clearance for an at-home heart rhythm test for diagnosing asymptomatic atrial fibrillation.
AliveCor hit a major turning point for its smartphone-based ECG technology with FDA clearance for a new algorithm that helps patients diagnose their own heart rhythms.